April Joy Damian1, Tamar Mendelson2, Deborah Agus3. 1. Johns Hopkins Bloomberg School of Public Health, Department of Mental Health, 624 North Broadway Street, Room 798, Baltimore, MD 21205, United States. Electronic address: adamian2@jhu.edu. 2. Johns Hopkins Bloomberg School of Public Health, Department of Mental Health, 624 North Broadway Street, Room 853, Baltimore, MD 21205, United States. Electronic address: tmendel1@jhu.edu. 3. Johns Hopkins Bloomberg School of Public Health, Department of Mental Health, 624 North Broadway Street, 8th Floor, Baltimore, MD 21205, United States. Electronic address: dagus2@jhu.edu.
Abstract
INTRODUCTION: Despite evidence for the efficacy of buprenorphine treatment in primary care, few studies have identified factors associated with treatment success, nor have such factors been evaluated in community settings. Identifying correlates of treatment success can facilitate the development of treatment models tailored for distinct populations, including low-income communities of color. The current study examined client-level socio-demographic factors associated with treatment success in community-based buprenorphine programs serving vulnerable populations. METHODS: Data were abstracted from client records for participants (N=445) who met DSM-IV criteria for opioid dependence and sought treatment at one of Behavioral Health Leadership Institute's two community-based recovery programs in Baltimore City from 2010 to 2015. Logistic regression estimated the odds ratios of treatment success (defined as retention in treatment for ≥90days) by sociodemographic predictors including age, race, gender, housing, legal issues and incarceration. RESULTS: The odds of being retained in treatment ≥90days increased with age (5% increase with each year of age; p<0.001), adjusting for other sociodemographic factors. Clients who reported unstable housing had a 41% decreased odds of remaining in treatment for 90 or more days compared to clients who lived independently at intake. Treatment success did not significantly differ by several other client-level characteristics including gender, race, employment, legal issues and incarceration. CONCLUSIONS: In vulnerable populations, the age factor appears sufficiently significant to justify creating models formulated for younger populations. The data also support attention to housing needs for people in treatment. Findings from this paper can inform future research and program development.
INTRODUCTION: Despite evidence for the efficacy of buprenorphine treatment in primary care, few studies have identified factors associated with treatment success, nor have such factors been evaluated in community settings. Identifying correlates of treatment success can facilitate the development of treatment models tailored for distinct populations, including low-income communities of color. The current study examined client-level socio-demographic factors associated with treatment success in community-based buprenorphine programs serving vulnerable populations. METHODS: Data were abstracted from client records for participants (N=445) who met DSM-IV criteria for opioid dependence and sought treatment at one of Behavioral Health Leadership Institute's two community-based recovery programs in Baltimore City from 2010 to 2015. Logistic regression estimated the odds ratios of treatment success (defined as retention in treatment for ≥90days) by sociodemographic predictors including age, race, gender, housing, legal issues and incarceration. RESULTS: The odds of being retained in treatment ≥90days increased with age (5% increase with each year of age; p<0.001), adjusting for other sociodemographic factors. Clients who reported unstable housing had a 41% decreased odds of remaining in treatment for 90 or more days compared to clients who lived independently at intake. Treatment success did not significantly differ by several other client-level characteristics including gender, race, employment, legal issues and incarceration. CONCLUSIONS: In vulnerable populations, the age factor appears sufficiently significant to justify creating models formulated for younger populations. The data also support attention to housing needs for people in treatment. Findings from this paper can inform future research and program development.
Authors: Amy M Daniels; Elizabeth Salisbury-Afshar; Adam Hoffberg; Deborah Agus; Michael I Fingerhood Journal: J Addict Med Date: 2014 Jan-Feb Impact factor: 3.702
Authors: Ira L Mintzer; Mark Eisenberg; Maria Terra; Casey MacVane; David U Himmelstein; Steffie Woolhandler Journal: Ann Fam Med Date: 2007 Mar-Apr Impact factor: 5.166
Authors: Bradley D Stein; Adam J Gordon; Mark Sorbero; Andrew W Dick; James Schuster; Carrie Farmer Journal: Drug Alcohol Depend Date: 2011-11-16 Impact factor: 4.492
Authors: Jessica A Dreifuss; Margaret L Griffin; Katherine Frost; Garrett M Fitzmaurice; Jennifer Sharpe Potter; David A Fiellin; Jeffrey Selzer; Mary Hatch-Maillette; Susan C Sonne; Roger D Weiss Journal: Drug Alcohol Depend Date: 2013-01-18 Impact factor: 4.492
Authors: Adam Viera; Daniel J Bromberg; Shannon Whittaker; Bryan M Refsland; Milena Stanojlović; Kate Nyhan; Frederick L Altice Journal: Epidemiol Rev Date: 2020-01-31 Impact factor: 6.222
Authors: Leigh V Panlilio; Samuel W Stull; William J Kowalczyk; Karran A Phillips; Jennifer R Schroeder; Jeremiah W Bertz; Massoud Vahabzadeh; Jia-Ling Lin; Mustapha Mezghanni; Edward V Nunes; David H Epstein; Kenzie L Preston Journal: Drug Alcohol Depend Date: 2019-07-16 Impact factor: 4.492
Authors: Benjamin A Howell; Lisa Puglisi; Katie Clark; Carmen Albizu-Garcia; Evan Ashkin; Tyler Booth; Lauren Brinkley-Rubinstein; David A Fiellin; Aaron D Fox; Kathleen F Maurer; Hsiu-Ju Lin; Kathryn McCollister; Sean Murphy; Diane S Morse; Shira Shavit; Karen Wang; Tyler Winkelman; Emily A Wang Journal: J Subst Abuse Treat Date: 2021-01-29
Authors: Claudia R Amura; Tanya R Sorrell; Mary Weber; Andrea Alvarez; Nancy Beste; Ursula Hollins; Paul F Cook Journal: Subst Abuse Treat Prev Policy Date: 2022-01-03